A meta-analysis and systematic review of thalidomide for patients with previously untreated multiple myeloma

Cancer Treatment Reviews

Volumn 34, Issue 5, 2008, Pages 442-452

  Hicks, Lisa K ^a   Haynes, Adam E ^b   Reece, Donna E ^c   Walker, Irwin R ^d   Herst, Jordan A ^e   Meyer, Ralph M ^f   Imrie, Kevin ^g  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

^e SUDBURY REGIONAL HOSPITAL   (Canada)

^f QUEEN S UNIVERSITY   (Canada)

^g SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

Adverse events; Meta analysis; Multiple myeloma; Systematic review; Thalidomide; Venous thromboembolism

Indexed keywords

ANTHRACYCLINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; INTERFERON; LOW MOLECULAR WEIGHT HEPARIN; MELPHALAN; PAMIDRONIC ACID; PREDNISONE; THALIDOMIDE; VINCRISTINE; WARFARIN; ZOLEDRONIC ACID;

AUTOLOGOUS STEM CELL TRANSPLANTATION; BRADYCARDIA; CLINICAL TRIAL; COCHRANE LIBRARY; COMBINATION CHEMOTHERAPY; CONSTIPATION; CYTOPENIA; DRUG EFFICACY; EMBASE; FATIGUE; HEALTH CARE ORGANIZATION; HUMAN; MAINTENANCE THERAPY; MEDLINE; META ANALYSIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; REVIEW; SENSITIVITY ANALYSIS; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW; VENOUS THROMBOEMBOLISM;

DISEASE PROGRESSION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MULTIPLE MYELOMA; THALIDOMIDE; TREATMENT OUTCOME;

EID: 46749133562     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrv.2008.02.003     Document Type: Review

References (28)

1. Myeloma Trialist Collaborative Group (MTCG). Combination chemotherapy versus melphalan and prednisone as treatment of multiple myeloma: an overview of 6,633 patients from 27 randomized trials. J Clin Oncol 16 (1998) 3832-3842
2. Attal M., Harousseau J.L., Stoppa A.M., et al. A prospective, randomised trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 335 (1996) 91-97
3. Child J.A., Morgan G.J., Davies F.E., et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 348 (2003) 1875-1883
4. In: Ries L.A.G., Harkins D., and Krapcho M. (Eds). SEER cancer statistics review, 1975-2003 (2006), National Cancer Institute, Bethesda (MD). [based on November 2005 SEER data submission, posted to the SEER web site, 2006]
5. Singhal S., Mehta J., Desikan R., et al. Anti-tumor activity of thalidomide in multiple myeloma. N Engl J Med 341 (1999) 1565-1571
6. Glasmacher A., Hahn C., Hoffmann F., et al. A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. Br J Haematol 132 (2006) 584-593
7. Palumbo A., Bringhen S., Caravita T., et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 367 (2006) 825-831 [Additional data provided by the authors]
8. Rajkumar S.V., Blood E., Vesole D., et al. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 24 (2006) 431-436
9. Attal M., Harousseau J.L., Leyvraz S., et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 108 (2006) 3289-3294
10. Rajkumar S.V., Hussein M., Catalano J., et al. A randomized, double-blind, placebo-controlled trial of thalidomide plus dexamethasone versus dexamethasone alone as primary therapy for newly diagnosed multiple myeloma. Blood (ASH Annual Meeting Abstracts) 108 (2006) 246 [Additional data provided by the authors].
11. Ludwig H., Drach J., Tóthová E., et al. Thalidomide-dexamethasone versus melphalan-prednisolone as first line treatment in elderly patients with multiple myeloma: an interim analysis. Blood (ASH Annual Meeting Abstracts) 106 (2005) 782. [accessed 13.11.2006].
12. Spencer A., Prince M., Roberts A.W., et al. First analysis of the Australasian Leukaemia and Lymphoma Group (ALLG) trial of thalidomide and alternate day prednisolone following autologous stem cell transplantation (ASCT) for patients with multiple myeloma (ALLG MM6). Blood (ASH Annual Meeting Abstracts) 108 (2006) 58 [Additional, up-dated data provided by the authors]
13. Blade J., Samson D., Reece D., et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 102 (1998) 1115-1123
14. Barlogie B., Tricot G., Anaissie E., et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 354 (2006) 1021-1030
15. DerSimonian R., and Laird N. Meta-analysis in clinical trials. Control Clin Trials 7 (1986) 177-188
16. Parmar M.K.B., Torri V., and Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statist Med 17 (1998) 2815-2834
17. Zervas K., Mihou D., Katodritou E., et al. VAD-doxil versus VAD-doxil plus thalidomide as initial treatment for multiple myeloma: results of a multicenter randomized trial of the Greek myeloma study group. Ann Oncol 18 (2007) 1369-1375
18. Minnema M.C., Breitkreutz I., Auwerda J.J.A., et al. Prevention of venous thrombo-embolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy. Leukemia 18 (2004) 2044-2046
19. Cochrane W.G. The combination of estimates from different experiments. Biometrics 10 (1954) 101-129
20. Higgins J.P.T., Thompson S.G., Deeks J.J., and Altman D.G. Measuring inconsistency in meta-analysis. Br Med J 327 (2003) 557-560
21. Facon T, Mary JY, Hulin C, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 2007;370:1209-18. Data on intention-to-treat response rates not in publication. [accessed 16.11.2006].
22. Goldschmidt H., Sonneveld P., Breitkreuz I., et al. HOVON50/GMMG-HD3-Trial: phase III study on the effect of thalidomide combined with high dose melphalan in myeloma patients up to 65 years. Blood (ASH Annual Meeting Abstracts) 106 (2005) 424
23. Hulin C., Virion J., Leleu X., et al. Comparison of melphalan-prednisone-thalidomide (MP-T) to melphalan-prednisone (MP) in patients 75 years of age or older with untreated multiple myeloma (MM). Preliminary results of the randomized, double-blind, placebo controlled IFM 01-01 trial. ASCO Meeting Abstracts (2007) 8001
24. Macro M., Divine M., Uzunhan Y., et al. Dexamethasone+thalidomide (Dex/Thal) compared to VAD as a pre-transplant treatment in newly diagnosed multiple myeloma (MM): a randomized trial. Blood (ASH Annual Meeting Abstracts) 108 (2006) 57
25. Abdelkefi A., Ladeb S., Torjman L., et al. Single autologous stem cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial. Blood 111 (2008) 1805-1810
26. Offidani M., Corvatta L., Polloni C., et al. Thalidomide treatment after ThaDD induction for multiple myeloma: first analysis of a prospective randomized study. Blood (ASH Annual Meeting Abstracts) 108 (2006) 3566
27. Browman G.P., Bergsagel D., Sicheri D., et al. Randomized trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 13 (1995) 2354-2360
28. Girling D., Parmar M., Stenning S., Stephens R., and Stewart L. Clinical trials in cancer principles and practice (2003), Oxford University Press, Oxford